Fundraising FoxSound Bioventures
Venture capitalMalmö · Seed–Growth · 9 people tracked
Find your way into Sound Bioventures
Each arrow is one introduction. Sign up to fill in the first one.
Ask Takahiro Shoji to introduce you to Yang Zhao
You →Takahiro · together at Baidu, Inc. →Yang
Ask Jamie Chen to introduce you to Casper Breum
You →Jamie · together at Artax Biopharma →Casper
Ask Sam Okafor to introduce you to Johan Kördel
You →Sam · together at Sound Bioventures →Johan
- Ester Sklarsky2 people can intro you
- Philip Brainin2 people can intro you
- Fredrik Lehmann2 people can intro you
Sign up to find every way you can get introduced to Sound Bioventures
- Your email: who you already know at Sound Bioventures, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Sound Bioventures team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Sound Bioventures backs private biopharmaceutical companies that are about to enter or already in clinical stages, focusing on specialty therapeutic areas and the development of new medicines. The firm invests internationally across Europe and the USA, having originated as a Danish-Swedish partnership rooted in the Greater Copenhagen 'Medicon Valley' region. It positions itself as a straightforward, transparent and long-term-oriented co-investor that prioritizes doing what is right for its portfolio companies.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website & curated & public directories
What they invest in
from 15 of 20 portfolio companiesBiotech ×13Healthtech ×10Medical Devices ×6Media & Entertainment ×4AI & Machine Learning ×1Deep Tech ×1Fintech ×1Longevity ×1
HQs:Sweden×2United States×2Denmark×1France×1United Kingdom×1
Investments · 20 tracked
founders shown can be your intro pathBy year:2024 · 12023 · 23 dated
AbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases.
BiotechHealthtech
Ignacio Anegon(Co-founder, Senior Consultant & SAB Member)inCarole Guillonneau(Co-founder & Head of Research)inFrançois-Xavier Hubert(Co-founder, Past President & Board Member)
Co-investorsCriteria Bio VenturesNewton BiocapitalSambrinvestWallonie Entreprendre
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investors3B Future Health FundIndustrifondenNovo HoldingsPureos Bioventures
Arthex Biotech develops antisense RNA compounds to treat diseases with unmet medical needs.
AI & Machine LearningBiotechMedical Devices
Beatriz Llamusí(Chief Scientific Officer & Co-Founder)in
Co-investorsHadean VenturesBpifranceColumbus Venture PartnersAdBio partnersInvivo Capital Partners
Teitur Trophics is a biotech company developing therapies that target the sortilin family of receptors (SorCS-receptor biology) to activate the brain's natural survival pathways and preserve brain function.
BiotechDeep TechHealthtechLongevityAarhus, DK
Simon Mølgaard(Co-founder & CEO)inAnders Dalby(Co-founder)inMathias Ollendorff(Co-founder)inSimon Glerup(Co-founder)in
Co-investorsIndustrifondenP53 InvestInnovestorSunstone Capital
Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.
BiotechHealthtech
Co-investorsEpidarex CapitalOxford Science EnterprisesTaiho Ventures, LLCM Ventures
VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.
BiotechHealthtechMedical Devices
Pieter Reitsma(Founder)inJohn Glasspool(Chief Executive Officer)in
Co-investorsBioGeneration VenturesInkefYsios CapitalEICEQT Life SciencesUNIIQ+2 more
Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression.
BiotechHealthtechCambridge, US
Damia Tormo(President, CEO, Treasurer and Founder)inJoe Suarez(Executive Officer)Maria Nichol(Executive Officer)inRobert W. Armstrong, Ph.D.(Executive Officer, Director)Rob Armstrong(CEO)in
BoardAndre Hoekema(Director)
Co-investorsAdvent Life SciencesColumbus Venture Partners
Biotech Finances is a French-language news and analysis publication covering the biotech, pharma and medtech industries, focusing on financing, mergers and acquisitions, clinical developments and listed biotech valuations.
BiotechMedia & Entertainment
BioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals.
BiotechMedia & EntertainmentMedical Devices
BOOST Pharma is developing BT-101, a mesenchymal stem cell therapy for Osteogenesis Imperfecta (brittle bone disease) in children, based on research from Karolinska Institutet in Sweden.
BiotechHealthtechStockholm, SE
Lilian Walther Jallow(Co-founder & CDO)Cecilia Gotherstrom(Co-founder and member of SAB)Hans T. Schambye(Chief Executive Officer)Tony Hall(Chief Medical Officer)Louise Himmelstrup(Chief Regulatory Officer)
Co-investorsIndustrifonden
Born2Invest is an online financial news publication covering markets, investing, crowdfunding, biotechnology, and cryptocurrency for a general investor audience.
FintechMedia & Entertainment
Breye Therapeutics is a biopharmaceutical company developing medicines for ophthalmologic and metabolic diseases, leveraging expertise in clinical development, manufacturing, and regulatory pathways.
BiotechMedical Devices
Ulrik Mouritzen(CEO)
Co-investorsNovo Holdings
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesPathway Bioventures4BIO Capital+1 more
Hoama Group develops care and living communities for older adults, including specialized facilities for elderly deaf people using British Sign Language.
HealthtechMedia & EntertainmentSocialStaplehurst, GB
Nephrodi is a biotechnology company developing treatments for kidney conditions, including the rare disease Nephrogenic Diabetes Insipidus (NDI).
BiotechHealthtechMedical DevicesSeattle, US
Jeff M. Sands, M.D.(Executive Officer)Jeff M. Sands(Chief Medical Officer & Founder)Janet D. Klein(Director of Biology & Founder)Rachael Hagan(President & Chief Executive Officer)inFred Callori(Director)Donna See(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AbolerisArthexBreye TherapeuticsShorturlTeitur
Portfolio news
latest coverage across their companiesLaingBuisson · laingbuissonnews.com · Sep 14, 2026
Frequently asked questions
- How many investments has Sound Bioventures made?
- Sound Bioventures has 20 tracked investments.
- What stage does Sound Bioventures invest at?
- Sound Bioventures invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does Sound Bioventures focus on?
- Sound Bioventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Sound Bioventures located?
- Sound Bioventures is headquartered in Malmö, SE.
- Does Sound Bioventures lead rounds?
- Yes, Sound Bioventures leads investment rounds.
- Who does Sound Bioventures co-invest with?
- Sound Bioventures most often shares deals with Criteria Bio Ventures, Epidarex Capital, Industrifonden, among 22 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.